SHANGHAI and SINGAPORE, Nov. 16, 2026 /PRNewswire/ — Delonix Bioworks, a clinical-stage biotechnology company pioneering next-generation outer membrane vesicle (OMV) vaccines, today announced that it has entered into a Research Collaboration Agreement with A*STAR Infectious Diseases Labs (A*STAR IDL), a research institute under Singapore’s Agency for Science, Technology and Research (A*STAR).

The collaboration aims to discover and develop novel OMV-based vaccine candidates targeting Klebsiella pneumoniae (K. pneumoniae). By combining Delonix’s proprietary pathogenic bacterial genome editing and OMV Plus™ platforms with A*STAR IDL’s strong capabilities in translational infectious disease research, clinical relevant bacterial isolates, and immunological evaluation, the collaboration also strengthens Singapore’s capabilities to translate infectious disease research towards potential interventions against antimicrobial-resistant pathogens.

K. pneumoniae is a leading cause of life-threatening pneumonia, bloodstream infections, and sepsis, posing severe risks to vulnerable patient populations. The World Health Organization (WHO) has classified carbapenem-resistant Enterobacterales, including K. pneumoniae, as critical-priority pathogens due to high levels of multi-drug resistance against standard clinical therapies [1,2,3].

Despite the significant public health burden, there are currently no licensed vaccines available for K. pneumoniae. Traditional vaccine approaches have been hindered by the pathogen’s extensive genetic diversity, thick capsular polysaccharides that mask conserved surface antigens, and high antigenic variation across hypervirulent and multidrug-resistant clinical lineages. Delonix’s engineered OMV approach offers a differentiated solution to overcome these barriers. By precisely editing the bacterial genome to modulate capsular interference, detoxify endotoxins, and enrich conserved native antigens on non-replicating vesicles, engineered OMVs has the potential to elicit potent innate and adaptive immune responses capable of broad cross-strain protection.

This partnership marks an important milestone in Delonix’s global strategy to build collaborative networks that accelerate the translation of next-generation bacterial vaccines. Driven by a shared commitment to combating antimicrobial resistance (AMR), Delonix and A*STAR IDL will leverage their complementary strengths to generate and evaluate vaccine candidates for safety, immunogenicity, and broad cross-strain protective potential, with the aim of advancing potential preventive approaches against drug-resistant K. pneumoniae.

About Delonix Bioworks

Delonix Bioworks is a clinical-stage biotechnology company at the forefront of developing next-generation genetically engineered bacterial vaccines. Leveraging its proprietary OMV Plus™ platform, the company produces high-yield, cost-effective, and precisely engineered outer membrane vesicles (OMVs) designed for superior antigen presentation and immunogenicity. Delonix is dedicated to advancing a robust pipeline of innovative bacterial vaccine candidates addressing critical unmet needs, including vaccines targeting meningococcal group B (MenB), pertussis, gonorrhoea, and K. pneumoniae infections. Its lead candidate, DX-104, is currently in Phase I clinical trials in Australia and China.

For more information, please visit https://delonixbio.com/.

Business Development & Strategic Partnerships

Email: bd@delonixbio.com

References

[1] WHO. WHO Bacterial Priority Pathogens List, 2024.

[2] WHO. Global Antibiotic Resistance Surveillance Report 2025.

[3] WHO. WHO Warns of Widespread Resistance to Common Antibiotics Worldwide. 2025.

 

Source link

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
You May Also Like

Chinese and International Cultural Figures Explores Heritage and Innovation in China's Hubei Province

WUHAN, China, May 22, 2026 /PRNewswire/ — From April 20 to 23,…

ZKH Group Limited to Announce Fourth Quarter and Fiscal Year 2025 Financial Results on Thursday, March 19, 2026

SHANGHAI, March 5, 2026 /PRNewswire/ — ZKH Group Limited ("ZKH" or the…

AI Can Make the Shot. Nura Showcraft Makes the Production.

Nura Studios launches Showcraft, a professional platform for filmmakers, animators and producers…